StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

Equities researchers at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Sunday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NeuroMetrix stock opened at $3.95 on Friday. The company’s 50-day moving average is $4.06 and its 200-day moving average is $3.84. The firm has a market capitalization of $8.07 million, a PE ratio of -0.86 and a beta of 2.18. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million for the quarter. During the same quarter in the previous year, the business posted ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.